Diverse genetic alterations in triple-negative breast cancers after neoadjuvant chemotherapy

Young women with breast cancer more likely to respond to neoadjuvant chemotherapy

Chemo after complete surgical removal of local or regional breast cancer recurrence increases survival rates

Fewer, bigger doses of radiotherapy benefit cancer patients

New genetic sub-types of breast, ovarian and prostate cancer

Benefits of participating in clinical trials and patient liaison groups

Effects of aspirin on the progression of cancer

Progress of personalised oncology treatment

Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST)

Standard of care for neo-adjuvant therapy in HER 2 and triple negative subtype

The Neo ALTO Study, combination therapy of lapatinib and trastuzumab and breast conservation surgery

Personalised cancer medicine and research: Today’s best practice